
Angioedema- Pipeline Insight, 2025
Description
DelveInsight’s, “Angioedema- Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Angioedema pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Angioedema: Overview
Angioedema is defined as ""subcutaneous tissues and/or submucosal tissues circumscribed non-pitting edema affecting lips, face, neck, and extremities oral cavity, larynx, and gut."" It becomes life-threatening when it involves the larynx, while intestinal angioedema is painful and mimics acute abdomen. In inherited (hereditary angioedema) mutations in the gene encoding for C1-inhibitor cause hereditary angioedema and it is an autosomal dominant condition. Hereditary angioedema is a rare disease that often leads to delay in diagnosis as well as a misdiagnosis. Other factors leading to a misdiagnosis are unknown family history, gastrointestinal manifestations of disease without cutaneous involvement. Angioedema is caused by an increase in local capillary permeability and plasma extravasation, usually mediated by mast cells, histamine, or bradykinin release. Angioedema is most commonly histamine-mediated; mast cell and basophil stimulation results in histamine release. Angioedema with urticaria tends to suggest a histaminergic form, which includes acute allergic angioedema and histaminergic idiopathic angioedema. The exact cause depends on the type of angioedema a patient has.
Symptoms of angioedema typically appear suddenly and may remain for up to 3 days. Swelling beneath the skin’s surface is the most common symptom of angioedema and may affect a person’s hands, genitals, feet, legs, eyes, throat, tongue, bowel lining. Other symptoms may include a hot, prickling, or painful sensation, an itchy, red rash (urticaria), impaired vision, abdominal pain, bladder problems and difficulty breathing.
The diagnosis of angioedema is based on appearance of symptoms and a description of what may have triggered symptoms requesting and reviewing a person’s family, medication, and medical history. If a person was exposed to a common allergen before angioedema occurred, allergic angioedema is likely. Alternatively, a family history of angioedema may suggest that angioedema presenting is hereditary. Tests used to diagnose the angioedema includes a skin prick test in which the skin is pricked with a very small amount of the suspected allergen, a blood test to see how the immune system reacts to a certain allergen, and a blood test to check for C1 esterase inhibitors, where low levels or dysfunction suggests the problem is hereditary. Treatment for angioedema depends on the type and cause, although most cases improve after a few days without treatment. Identifying and avoiding an allergen that may have caused angioedema is key to preventing further symptoms. If intervention is required, medications prescribed may include antihistamines, corticosteroids, epinephrine (EpiPen). If the cause is hereditary, there is no cure. However, a person may receive several types of treatment to help prevent angioedema symptoms, such as receiving specialized medications, a concentrate of the C1 inhibitor the protein they are missing and fresh frozen plasma. If a person experiences sudden swelling or trouble breathing, urgent medical attention is required. The most important action is to ensure a free airway, so a breathing tube might be placed for safety.
""Angioedema- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Angioedema pipeline landscape is provided which includes the disease overview and Angioedema treatment guidelines. The assessment part of the report embraces, in depth Angioedema commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Angioedema collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Angioedema report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Angioedema Emerging Drugs
Further product details are provided in the report……..
Angioedema: Therapeutic Assessment
This segment of the report provides insights about the different Angioedema drugs segregated based on following parameters that define the scope of the report, such as:
Angioedema: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Angioedema therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Angioedema drugs.
Angioedema Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Angioedema: Overview
Angioedema is defined as ""subcutaneous tissues and/or submucosal tissues circumscribed non-pitting edema affecting lips, face, neck, and extremities oral cavity, larynx, and gut."" It becomes life-threatening when it involves the larynx, while intestinal angioedema is painful and mimics acute abdomen. In inherited (hereditary angioedema) mutations in the gene encoding for C1-inhibitor cause hereditary angioedema and it is an autosomal dominant condition. Hereditary angioedema is a rare disease that often leads to delay in diagnosis as well as a misdiagnosis. Other factors leading to a misdiagnosis are unknown family history, gastrointestinal manifestations of disease without cutaneous involvement. Angioedema is caused by an increase in local capillary permeability and plasma extravasation, usually mediated by mast cells, histamine, or bradykinin release. Angioedema is most commonly histamine-mediated; mast cell and basophil stimulation results in histamine release. Angioedema with urticaria tends to suggest a histaminergic form, which includes acute allergic angioedema and histaminergic idiopathic angioedema. The exact cause depends on the type of angioedema a patient has.
Symptoms of angioedema typically appear suddenly and may remain for up to 3 days. Swelling beneath the skin’s surface is the most common symptom of angioedema and may affect a person’s hands, genitals, feet, legs, eyes, throat, tongue, bowel lining. Other symptoms may include a hot, prickling, or painful sensation, an itchy, red rash (urticaria), impaired vision, abdominal pain, bladder problems and difficulty breathing.
The diagnosis of angioedema is based on appearance of symptoms and a description of what may have triggered symptoms requesting and reviewing a person’s family, medication, and medical history. If a person was exposed to a common allergen before angioedema occurred, allergic angioedema is likely. Alternatively, a family history of angioedema may suggest that angioedema presenting is hereditary. Tests used to diagnose the angioedema includes a skin prick test in which the skin is pricked with a very small amount of the suspected allergen, a blood test to see how the immune system reacts to a certain allergen, and a blood test to check for C1 esterase inhibitors, where low levels or dysfunction suggests the problem is hereditary. Treatment for angioedema depends on the type and cause, although most cases improve after a few days without treatment. Identifying and avoiding an allergen that may have caused angioedema is key to preventing further symptoms. If intervention is required, medications prescribed may include antihistamines, corticosteroids, epinephrine (EpiPen). If the cause is hereditary, there is no cure. However, a person may receive several types of treatment to help prevent angioedema symptoms, such as receiving specialized medications, a concentrate of the C1 inhibitor the protein they are missing and fresh frozen plasma. If a person experiences sudden swelling or trouble breathing, urgent medical attention is required. The most important action is to ensure a free airway, so a breathing tube might be placed for safety.
""Angioedema- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Angioedema pipeline landscape is provided which includes the disease overview and Angioedema treatment guidelines. The assessment part of the report embraces, in depth Angioedema commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Angioedema collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Angioedema R&D. The therapies under development are focused on novel approaches to treat/improve Angioedema.
This segment of the Angioedema report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Angioedema Emerging Drugs
- Donidalorsen: Ionis Pharmaceuticals
- NTLA-2002: Intellia Therapeutics
- STAR-0215: Astria Therapeutics, Inc
Further product details are provided in the report……..
Angioedema: Therapeutic Assessment
This segment of the report provides insights about the different Angioedema drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Angioedema
- There are approx. 20+ key companies which are developing the therapies for Angioedema. The companies which have their Angioedema drug candidates in the most advanced stage, i.e. phase III include, Ionis Pharmaceuticals.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Angioedema: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Angioedema therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Angioedema drugs.
Angioedema Report Insights
- Angioedema Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Angioedema drugs?
- How many Angioedema drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Angioedema?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Angioedema therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Angioedema and their status?
- What are the key designations that have been granted to the emerging drugs?
- Ionis Pharmaceuticals, Inc.
- Astria Therapeutics, Inc.
- Intellia Therapeutics
- BioMarin Pharmaceutical
- Incyte Corporation
- Novartis
- KalVista Pharmaceuticals, Ltd.
- Sanofi
- Pharvaris Netherlands B.V.
- ADARx Pharmaceuticals, Inc.
- CSL Behring
- CAMP4 Therapeutics
- Donidalorsen
- STAR-0215
- NTLA-2002
- BMN 331
- Povorcitinib
- LOU064
- KVD900
- Dupilumab
- Deucrictibant
- ADX-324
- Garadacimab
- Research programme: liver disorder therapeutic
Table of Contents
80 Pages
- Introduction
- Executive Summary
- Angioedema: Overview
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Angioedema– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Donidalorsen: Ionis Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- NTLA-2002: Intellia Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Angioedema Key Companies
- Angioedema Key Products
- Angioedema- Unmet Needs
- Angioedema- Market Drivers and Barriers
- Angioedema- Future Perspectives and Conclusion
- Angioedema Analyst Views
- Angioedema Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.